Supreme Court Case Could Upend Bipartisan Law Accelerating Generic Drugs

The Supreme Court is set to decide a case involving 'skinny labels' that could disrupt a bipartisan law designed to accelerate generic drug launches. This legislation has historically saved American patients, employers, and taxpayers significant money by ensuring timely access to affordable medications. A ruling against the current framework could lead to higher drug prices and reduced access to essential treatments for millions.